HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vibha Ravi

Latest From Vibha Ravi

J&J’s Gorsky Offers Leadership Lessons As He Gets Set To Advise Apple

After 34 years of seeing and shaping Johnson & Johnson’s future, executive chair Alex Gorsky has recently joined Apple’s board of directors. At a recent event, he shared lessons for future leaders while unraveling some of the thinking behind decisions taken as chair and CEO

Commercial Business Strategies

COVID-19 Vaccine Pediatric Landscape In India - Biological E Scores, Zydus At Zero

India’s COVID-19 immunization focus has shifted to children as over 88% adults are fully vaccinated. However, Scrip’s examination of weekly data reveals the number of doses given to children are also dropping sharply off peaks. Meanwhile, Biological E is winning over others like Novavax in this segment while Zydus Lifesciences is yet to score

Commercial Coronavirus COVID-19

Aurobindo Expects To Be In Top Three For Immunology Biosimilar – Is It Xolair?

Aurobindo is aiming for a regulatory filing in FY24/25 of its first immunology biosimilar, potentially a version of Novartis/Roche’s Xolair. Meanwhile, a pneumococcal vaccine is expected to be filed in India in the second half of FY23.

Strategy Sales & Earnings

Strides Founder Back As MD, Asserts Confidence In US As Company Exits Parts Of Europe

Back as Strides managing director, founder Arun Kumar is confident of reversing a slide in profits via a recalibration strategy that saw the company exit Canada and a few European markets. Meanwhile, eyes are on the fallout of a CRO that serviced Strides apart from Sandoz, Teva and more getting caught in CHMP and FDA’s crosshairs.

Strategy Sales & Earnings

Aurobindo Expects To Be In Top Three For Immunology Biosimilar - Is It Xolair?

Aurobindo is aiming for a regulatory filing in FY24/25 of its first immunology biosimilar. Scrip examines if it could it be a biosimilar to Novartis/Roche’s Xolair. Meanwhile, a pneumococcal vaccine is expected to be filed in India in the second half of FY23

Research & Development Biosimilars

Torrent Acquires Chronic Brands From Dr Reddy’s, Folds Up US Liquids Business

Torrent is recalibrating strategy with the addition of chronic therapies from Dr Reddy’s while it folds up an unsustainable liquids business in US. The latter resulted in the company reporting a Q4 loss but a timely bonus share issue propped up investor sentiment.

Deals Strategy
See All
UsernamePublicRestriction

Register